180 related articles for article (PubMed ID: 34661159)
1. Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins.
Maimaitiyiming Y; Wang QQ; Yang C; Ogra Y; Lou Y; Smith CA; Hussain L; Shao YM; Lin J; Liu J; Wang L; Zhu Y; Lou H; Huang Y; Li X; Chang KJ; Chen H; Li H; Huang Y; Tse E; Sun J; Bu N; Chiou SH; Zhang YF; Hua HY; Ma LY; Huang P; Ge MH; Cao FL; Cheng X; Sun H; Zhou J; Vasliou V; Xu P; Jin J; Bjorklund M; Zhu HH; Hsu CH; Naranmandura H
Blood Cancer Discov; 2021 Jul; 2(4):388-401. PubMed ID: 34661159
[TBL] [Abstract][Full Text] [Related]
2. Hyperthermia promotes degradation of the acute promyelocytic leukemia driver oncoprotein ZBTB16/RARα.
Wang QQ; Hussain L; Yu PH; Yang C; Zhu CY; Ma YF; Wang SC; Yang T; Kang YY; Yu WJ; Maimaitiyiming Y; Naranmandura H
Acta Pharmacol Sin; 2023 Apr; 44(4):822-831. PubMed ID: 36216898
[TBL] [Abstract][Full Text] [Related]
3. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
4. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia.
Guo Y; Dolinko AV; Chinyengetere F; Stanton B; Bomberger JM; Demidenko E; Zhou DC; Gallagher R; Ma T; Galimberti F; Liu X; Sekula D; Freemantle S; Dmitrovsky E
Cancer Res; 2010 Dec; 70(23):9875-85. PubMed ID: 20935222
[TBL] [Abstract][Full Text] [Related]
5. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
Ohnishi K
Int J Clin Oncol; 2007 Oct; 12(5):313-7. PubMed ID: 17929112
[TBL] [Abstract][Full Text] [Related]
6. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy.
Ding W; Li YP; Nobile LM; Grills G; Carrera I; Paietta E; Tallman MS; Wiernik PH; Gallagher RE
Blood; 1998 Aug; 92(4):1172-83. PubMed ID: 9694705
[TBL] [Abstract][Full Text] [Related]
7. Targeting of PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells.
Nason-Burchenal K; Allopenna J; Bègue A; Stéhelin D; Dmitrovsky E; Martin P
Blood; 1998 Sep; 92(5):1758-67. PubMed ID: 9716606
[TBL] [Abstract][Full Text] [Related]
8. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
[TBL] [Abstract][Full Text] [Related]
10. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
[TBL] [Abstract][Full Text] [Related]
11. The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RARα and overcomes ATRA resistance in acute promyelocytic leukemia cells.
Franza M; Albanesi J; Mancini B; Pennisi R; Leone S; Acconcia F; Bianchi F; di Masi A
Biochem Pharmacol; 2023 Aug; 214():115675. PubMed ID: 37406967
[TBL] [Abstract][Full Text] [Related]
12. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
[TBL] [Abstract][Full Text] [Related]
13. Autophagy and Ubiquitin-Mediated Proteolytic Degradation of PML/Rarα Fusion Protein in Matrine-Induced Differentiation Sensitivity Recovery of ATRA-Resistant APL (NB4-LR1) Cells: in Vitro and in Vivo Studies.
Wu D; Shao K; Zhou Q; Sun J; Wang Z; Yan F; Liu T; Wu X; Ye B; Huang H; Zhou Y
Cell Physiol Biochem; 2018; 48(6):2286-2301. PubMed ID: 30114705
[TBL] [Abstract][Full Text] [Related]
14. Influence of bcr-3 PML-RARα transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic tri-oxide.
Baba SM; Shah ZA; Pandith AA; Dil-Afroze ; Jan A; Mir KA; Aziz SA; Ahmad Z
Cancer Genet; 2019 Feb; 231-232():14-21. PubMed ID: 30803552
[TBL] [Abstract][Full Text] [Related]
15. Acute promyelocytic leukemia and variant fusion proteins: PLZF-RARα fusion protein at a glance.
Hussain L; Maimaitiyiming Y; Islam K; Naranmandura H
Semin Oncol; 2019 Apr; 46(2):133-144. PubMed ID: 31126665
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia.
Imaizumi M; Suzuki H; Yoshinari M; Sato A; Saito T; Sugawara A; Tsuchiya S; Hatae Y; Fujimoto T; Kakizuka A; Konno T; Iinuma K
Blood; 1998 Jul; 92(2):374-82. PubMed ID: 9657734
[TBL] [Abstract][Full Text] [Related]
17. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.
Tabe Y; Konopleva M; Kondo Y; Contractor R; Jin L; Ruvolo V; Tsutsumi-Ishii Y; Miyake K; Miyake N; Ohsaka A; Nagaoka I; Issa JP; Andreeff M
Ann Hematol; 2006 Oct; 85(10):689-704. PubMed ID: 16832676
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia.
Grimwade D; Gorman P; Duprez E; Howe K; Langabeer S; Oliver F; Walker H; Culligan D; Waters J; Pomfret M; Goldstone A; Burnett A; Freemont P; Sheer D; Solomon E
Blood; 1997 Dec; 90(12):4876-85. PubMed ID: 9389704
[TBL] [Abstract][Full Text] [Related]
19. Skp2 promotes APL progression through the stabilization of oncoprotein PML-RARα and the inhibition of JunB expression.
Dan W; Zhong L; Yu L; Xiong L; Li J; Ye J; Luo X; Liu C; Chu X; Liu B
Life Sci; 2022 Jan; 289():120231. PubMed ID: 34921867
[TBL] [Abstract][Full Text] [Related]
20. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein.
Nervi C; Ferrara FF; Fanelli M; Rippo MR; Tomassini B; Ferrucci PF; Ruthardt M; Gelmetti V; Gambacorti-Passerini C; Diverio D; Grignani F; Pelicci PG; Testi R
Blood; 1998 Oct; 92(7):2244-51. PubMed ID: 9746761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
